Prescribing Information

Home / Efficacy / Patient Profiles

Plan early for TECARTUS® in your adult patients with R/R B-cell ALL

ALL PATIENT CASE (2L)

Act urgently following relapsed/refractory B-ALL with TECARTUS

Headshot of a female representing TECARTUS® patient.
Clinical considerations

59-year-old female with B-cell acute lymphoblastic leukemia (B-ALL)

  • Immunohistochemistry: CD19+, CD20+, and CD22+
  • Cytogenetics: Ph-negative
  • BM biopsy: 65% blasts

MRD: Persistent positive by flow cytometry

LDH: 520 U/L

ECOG PS: 1

Comorbidities: None significant

Clinical fitness
  • Cardiac function: LVEF 55%
  • Renal function: CrCl 80 mL/min
  • Liver function: Mild AST/ALT elevation
Treatment History
Newly diagnosed ALL First line:
  • Hyper-CVAD (progression within 11 months)
Results:
  • Bone marrow biopsy confirms relapse with rising lymphoblasts after frontline therapy
Comments:
  • Relapsed/refractory disease after frontline treatment
  • High disease burden (increased blasts, increased LDH)
  • Rapid progression following prior therapy
  • Clinically fit with preserved organ function
Treatment Considerations:
  • Limited treatment options with durable responses in R/R ALL
  • Rapid disease progression requires timely intervention
  • Eligible for CAR T, given ECOG 1 and preserved organ function
  • Early referral critical to avoid further clinical deterioration

TECARTUS offers the potential for deep and durable responses with timely treatment, supported by rapid, reliable, and experienced manufacturing

ALL PATIENT CASE (MRD POSITIVE)

Early CAR T consultation and recognition of persistent MRD may help identify patients who could benefit from timely referral for TECARTUS before relapse occurs

Headshot of a male representing TECARTUS® patient.
Clinical considerations

41-year-old male with B-cell acute lymphoblastic leukemia (B-ALL)

  • Immunohistochemistry: CD19+, CD22+
  • Cytogenetics: Ph-negative
  • BM biopsy: <5% blasts (morphologic remission)

MRD: Persistent positive by flow cytometry

LDH: 240 U/L

Clinical fitness
  • Cardiac function: LVEF 62%
  • Renal function: CrCl 95 mL/min
  • Liver function: WNL
  • ECOG PS: 0
  • Comorbidities: Mild HTN
Treatment History
Newly diagnosed ALL Induction and consolidation:
  • Hyper-CVAD + rituximab → Morphologic CR
Maintenance:
  • Persistent MRD positivity after consolidation
  • Received blinatumomab → MRD persistence
Results:
  • Persistent MRD despite sequential therapy
  • No overt morphologic relapse, but concern for impending progression
  • Referred early while clinically stable and fit
Comments:
  • Persistent MRD associated with increased relapse risk
  • Young, functionally fit patient with preserved organ function
  • Early referral may offer opportunity for CAR T before overt clinical deterioration
  • Motivated to pursue a potentially durable treatment approach
Treatment Considerations:
  • MRD persistence suggests high-risk disease despite morphologic remission
  • Additional sequential therapy may not overcome resistant disease biology
  • Eligible for CAR T given ECOG PS 0 and preserved organ function

Early recognition of persistent MRD may help identify patients who could benefit from timely referral for TECARTUS

For adults with R/R B-cell ALL, plan for CAR T‐cell therapy

Educate patients about CAR T-cell therapy

Determine eligibility for future CAR T treatment

ALL=acute lymphoblastic leukemia; allo-SCT=allogeneic stem cell transplant; B-ALL=B-cell acute lymphoblastic leukemia; BM=bone marrow; CALGB 10403 regimen=daunorubicin, vincristine, prednisone, and pegaspargase; CAR=chimeric antigen receptor; CD=cluster of differentiation; CR=complete remission; CR1=first complete remission; CR2=second complete remission; CrCl=creatinine clearance; ECOG PS=Eastern Cooperative Oncology Group performance status; HTN=hypertension; hyper-CVAD=hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; MRD=minimal residual disease; Ph=Philadelphia chromosome; POMP=methotrexate, 6-mercaptopurine, vincristine, and prednisone; R/R=relapsed or refractory; WNL=within normal limits.

References: 1. Gökbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524-1533. 2. TECARTUS® (brexucabtagene autoleucel). Prescribing Information. Kite Pharma, Inc; 2026. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.1.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed April 9, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org.

Up next: Overall Safety Profile >